chevron_leftBack
As of 14 June 2026, Arcutis Biotherapeutics, Inc. has a market cap of $2.8B USD, ranking #5693 globally and #1500 in the United States.
It ranks #447 in the Healthcare sector, and #175 in the Drug Manufacturers - General industry.
Key Stats
Market Cap
$2.8BUSD
Enterprise Value
$2.67BUSD
Revenue (TTM)
$376.07MUSD
EBITDA (TTM)
-$7.56MUSD
Net Income (TTM)
-$16.14MUSD
EBITDA Margin
-2%
Profit Margin
-4.3%
Forward PE
78.0
PS Ratio
7.4
PB Ratio
15.2
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Todd Watanabe
open_in_new
Employees
354
Founded
2016
IPO
31 Jan 2020
Website
arcutis.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -3.8% | -5.8% | 5.4% | -12% | -10% | 54% |
News
Loading...
ARQT Analyst Forecasts
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
ARQT
Arcutis Biotherapeutics Inc Ordinary Shares
ISIN: US03969K1088
Shares Out.:
Shares Outstanding:
125.083M1
Shares Float:
110.424M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
22.40 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Arcutis Biotherapeutics, Inc.
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company’s lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 receptor. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NYSE: LLY
|
$761.68B
27K%
|
38.1
|
|
NYSE: JNJ
|
$547.28B
19K%
|
26.4
|
|
NYSE: ABBV
|
$360.63B
13K%
|
97.4
|
|
NYSE: MRK
|
$274.03B
10K%
|
15.1
|
|
NYSE: PFE
|
$149.38B
5K%
|
19.5
|
|
NYSE: BMY
|
$117.58B
4K%
|
16.8
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
SIX: RO
|
$321.52B
11K%
256.25B CHF
|
19.9
|
|
LSE: AZN
|
$288.84B
10K%
215.59B GBP
|
27.6
|
|
SIX: NOVN
|
$274.65B
10K%
218.9B CHF
|
20.5
|
|
CPH: NOVO-B
|
$181.82B
6K%
1.18T DKK
|
11.5
|
|
EPA: SAN
|
$110.1B
4K%
95.26B EUR
|
19.9
|
|
LSE: GSK
|
$108.46B
4K%
80.96B GBP
|
14.6
|
chevron_leftBack